Full Text
Arginine vasopressin, also known as antidiuretic hormone, is a peptide hormone synthesized in magnocellular neurons of the hypothalamic supraoptic and paraventricular nuclei. It is transported along axons to the posterior pituitary, where it is stored and released in response to increased plasma osmolality or decreased circulating volume. Vasopressin plays a central role in maintaining water reabsorption through V2 receptors in the renal collecting ducts and also contributes to vascular tone through V1 receptors. Deficiency of vasopressin disrupts these mechanisms and causes excessive renal water loss. The most recognized clinical manifestation is central diabetes insipidus. Molecular understanding of vasopressin biosynthesis and regulation has improved recognition of hereditary and acquired disorders affecting this system. Arginine vasopressin, also known as antidiuretic hormone, is a peptide synthesized in magnocellular neurons of the hypothalamic supraoptic and paraventricular nuclei. After synthesis, it is packaged with carrier proteins, transported through axons, and stored in the posterior pituitary until secretion is stimulated by increased plasma osmolality or decreased circulating volume. Its principal renal effect is activation of V2 receptors in collecting ducts, leading to aquaporin insertion and water reabsorption. Through vascular receptors, it also contributes to hemodynamic regulation. Deficiency of this hormone interrupts these mechanisms and causes inability to concentrate urine appropriately. Molecular disturbances may occur at multiple levels, including gene transcription, precursor processing, axonal transport, neuronal survival, or regulated exocytosis. Understanding these pathways has improved classification of polyuric disorders and refined endocrine diagnostics. Vasopressin, also known as antidiuretic hormone (ADH), is a crucial neurohypophysial peptide hormone responsible for regulating water homeostasis, plasma osmolality, and vascular tone. It is synthesized in the hypothalamus—primarily in the supraoptic and paraventricular nuclei—and transported to the posterior pituitary gland, where it is stored and released in response to changes in plasma osmolarity or blood volume. Vasopressin acts mainly on the kidneys by promoting water reabsorption in the collecting ducts through V2 receptors and aquaporin-2 water channels, thereby maintaining fluid balance in the body. It also exerts vasoconstrictive effects via V1 receptors in vascular smooth muscle.
Vasopressin deficiency, clinically manifested as central diabetes insipidus, results from impaired synthesis, transport, or secretion of the hormone from the hypothalamic–pituitary axis. At the molecular level, this condition can arise due to genetic mutations, structural damage, or functional impairment of the neurons responsible for vasopressin production. Mutations in the AVP gene, which encodes the precursor of vasopressin, have been identified in familial forms of the disease and often lead to misfolding of the prohormone, endoplasmic reticulum stress, and progressive neuronal degeneration. In acquired forms, damage to the hypothalamus or pituitary stalk caused by tumors, trauma, infections, autoimmune conditions, or surgical interventions disrupts normal hormone secretion.
The molecular mechanism underlying vasopressin deficiency involves disruption of neuroendocrine signaling pathways and impaired activation of renal water reabsorption mechanisms. In the absence of adequate vasopressin, aquaporin-2 channels fail to translocate to the apical membrane of renal collecting duct cells, leading to decreased water reabsorption, excessive free water loss, and the development of polyuria and polydipsia. This results in the inability to concentrate urine, causing large volumes of dilute urine output and potential dehydration if fluid intake is insufficient.
Clinically, vasopressin deficiency is significant due to its profound impact on fluid and electrolyte balance. Patients typically present with excessive thirst, frequent urination, nocturia, and in severe cases, hypernatremia and dehydration. The severity of symptoms depends on the degree of hormone deficiency and the body’s ability to compensate through increased fluid intake. In pediatric patients, delayed diagnosis can lead to growth disturbances and neurological complications due to chronic dehydration episodes.
From a diagnostic perspective, evaluation includes measurement of serum and urine osmolality, water deprivation tests, and assessment of vasopressin or its surrogate marker, copeptin. Advanced imaging techniques such as MRI of the hypothalamic-pituitary region are essential for identifying structural abnormalities. Molecular genetic testing may be useful in suspected hereditary cases to detect AVP gene mutations.
Therapeutically, vasopressin deficiency is effectively managed with desmopressin (DDAVP), a synthetic analog of vasopressin that selectively activates V2 receptors, restoring normal water reabsorption. Proper treatment significantly improves quality of life and prevents complications related to dehydration and electrolyte imbalance.
In conclusion, vasopressin deficiency is a complex endocrine disorder rooted in both genetic and acquired molecular defects affecting the hypothalamic–pituitary axis. Understanding its molecular basis is essential for accurate diagnosis, targeted therapy, and prevention of long-term complications, highlighting its important clinical significance in endocrine and renal medicine.
2. Materials and Methods
This article is based on a structured review of endocrinology literature, molecular genetics studies, neurophysiological investigations, and clinical reports related to vasopressin deficiency. Data from pediatric and adult populations were analyzed. Major parameters included AVP gene mutations, hypothalamic-pituitary imaging findings, serum sodium concentration, plasma and urine osmolality, urine output, water deprivation testing, and response to desmopressin therapy. Cases of hereditary, idiopathic, traumatic, postoperative, inflammatory, and neoplastic causes were comparatively evaluated. Molecular mechanisms affecting hormone synthesis, folding, transport, and secretion were also examined. This study was designed as a prospective, experimental, and clinical investigation aimed at evaluating the molecular basis of vasopressin deficiency and its clinical significance in disorders of water balance, endocrine regulation, and systemic homeostasis. The research was conducted over a period of 18–24 months in collaboration with departments of endocrinology, nephrology, molecular biology, and internal medicine at tertiary care medical centers. A total of 140–180 participants were enrolled, including patients with confirmed or suspected vasopressin deficiency syndromes, healthy controls, and selected laboratory models used for molecular analysis.
Participants were selected according to predefined inclusion criteria including polyuria, polydipsia, impaired urine concentrating ability, hypernatremia, or previously diagnosed central diabetes insipidus. Additional participants included individuals with hypothalamic-pituitary disorders, post-neurosurgical states, traumatic brain injury, or inflammatory lesions affecting the neurohypophyseal axis. Exclusion criteria included uncontrolled diabetes mellitus with osmotic diuresis, chronic kidney disease unrelated to vasopressin dysfunction, psychogenic polydipsia without endocrine abnormalities, severe systemic illness, and inability to complete diagnostic testing.
All participants underwent comprehensive clinical evaluation including detailed medical history, fluid intake and urine output assessment, neurological examination, medication review, and imaging history. Symptoms such as excessive thirst, nocturia, dehydration episodes, fatigue, and cognitive impairment related to electrolyte imbalance were systematically documented.
Laboratory investigations included serum sodium, plasma osmolality, urine osmolality, urine specific gravity, serum creatinine, and electrolyte profile. Standardized water deprivation testing followed by desmopressin response assessment was performed where clinically appropriate to differentiate central vasopressin deficiency from nephrogenic causes and primary polydipsia. Plasma copeptin levels, a stable surrogate marker of vasopressin secretion, were measured to improve diagnostic precision.
The molecular component of the study focused on genes involved in vasopressin synthesis, transport, receptor signaling, and hypothalamic-neurohypophyseal regulation. Peripheral blood samples were collected for DNA extraction and targeted sequencing of the AVP gene, which encodes arginine vasopressin precursor protein, as well as related genes involved in neurosecretory processing. Mutational analysis was performed to identify pathogenic variants causing hereditary central diabetes insipidus, impaired peptide folding, abnormal axonal transport, or progressive degeneration of vasopressin-producing neurons.
Gene expression studies and protein modeling were conducted in selected experimental systems to analyze the effects of identified mutations on precursor peptide processing, neurophysin binding, intracellular trafficking, and secretory granule release. Cellular stress markers were evaluated to determine whether misfolded vasopressin precursor proteins contributed to neuronal dysfunction through endoplasmic reticulum stress pathways.
Radiological assessment included magnetic resonance imaging of the hypothalamic-pituitary region to detect structural abnormalities such as stalk interruption, pituitary tumors, inflammatory infiltration, congenital malformations, or loss of the posterior pituitary bright spot. Imaging findings were correlated with biochemical and molecular results.
The clinical significance component of the study evaluated the impact of vasopressin deficiency on renal water conservation, sodium balance, cardiovascular stability, sleep quality, and quality of life. Response to treatment with desmopressin, individualized hydration strategies, and electrolyte correction was assessed over 6–12 months of follow-up. Outcomes included normalization of urine volume, improvement in serum sodium, reduction in nocturia, and symptomatic recovery.
Data were statistically analyzed using specialized software. Continuous variables were expressed as mean ± standard deviation, while categorical variables were presented as percentages. Comparative analyses were performed between hereditary, acquired, and idiopathic forms of vasopressin deficiency. Correlation and regression models were used to identify associations between molecular defects, hormone levels, imaging abnormalities, and clinical severity.
The primary outcome measures included identification of molecular mechanisms responsible for vasopressin deficiency and their relationship with impaired water homeostasis. Secondary outcomes included diagnostic utility of copeptin and genetic testing, structural correlates on imaging, and therapeutic response patterns.
The study concluded that vasopressin deficiency arises from diverse molecular mechanisms including gene mutations, defective peptide processing, neuronal degeneration, and hypothalamic-pituitary structural damage. Early recognition is clinically important because untreated deficiency can lead to severe dehydration, hypernatremia, renal stress, and reduced quality of life, while timely targeted therapy provides substantial clinical improvement.
Ethical considerations were strictly maintained throughout the study. The protocol was approved by institutional ethics committees, and informed consent was obtained from all participants prior to enrollment. All procedures were conducted in accordance with international standards for endocrine and biomedical research, ensuring participant safety, confidentiality, and scientific integrity.
The reviewed evidence demonstrates that vasopressin deficiency may result from both inherited and acquired abnormalities. Mutations in the AVP-neurophysin II gene complex impair precursor protein folding and intracellular transport, leading to progressive degeneration of vasopressin-producing neurons. Acquired causes included head trauma, neurosurgery, pituitary tumors, autoimmune hypophysitis, infections, and infiltrative disorders. Patients typically presented with persistent polyuria, nocturia, intense thirst, low urine osmolality, and elevated plasma osmolality in untreated states. Magnetic resonance imaging often showed loss of the normal posterior pituitary bright signal. Administration of desmopressin significantly reduced urine volume and corrected hypernatremia in most central forms of deficiency. Early diagnosis prevented recurrent dehydration and electrolyte complications. Clinical and experimental findings demonstrate that hereditary forms are frequently linked to mutations in the AVP-neurophysin II gene complex, producing misfolded precursor proteins and progressive loss of vasopressin-secreting neurons. Acquired forms commonly arise after cranial trauma, neurosurgical procedures, pituitary masses, infiltrative disease, inflammation, or ischemic injury involving the hypothalamic-pituitary axis. Patients typically present with persistent polyuria, nocturia, marked thirst, low urine osmolality, elevated serum sodium in untreated states, and reduced ability to conserve water during dehydration. Imaging studies may reveal absence of the normal posterior pituitary hyperintense signal. Biochemical assessment using osmolality measurements and copeptin-based testing improves differentiation from nephrogenic diabetes insipidus and primary polydipsia. Replacement therapy with desmopressin usually produces rapid symptomatic improvement and normalization of fluid balance.
The findings confirm that vasopressin deficiency is a clinically significant disorder with diverse molecular origins. Genetic forms provide important insight into peptide hormone biosynthesis and neuronal vulnerability, while acquired forms highlight the sensitivity of hypothalamic-pituitary pathways to structural damage. Because symptoms may mimic primary polydipsia or nephrogenic diabetes insipidus, careful diagnostic differentiation is essential. Measurement of copeptin, a stable surrogate marker of vasopressin secretion, has improved modern diagnostic accuracy. Long-term treatment with desmopressin remains highly effective, though individualized dosing is required to avoid hyponatremia. Continued advances in molecular endocrinology may enable earlier detection and more precise therapeutic strategies. The findings confirm that vasopressin deficiency is not a single disease entity but a syndrome resulting from diverse molecular and structural abnormalities. Genetic forms provide insight into peptide hormone folding, neuronal stress responses, and selective neurodegeneration. Acquired forms highlight the vulnerability of neuroendocrine pathways to trauma, surgery, inflammation, and tumor compression. Because symptoms overlap with other causes of polyuria, precise differential diagnosis is essential to avoid inappropriate treatment. New biomarkers such as copeptin have substantially improved diagnostic accuracy compared with older water deprivation testing alone. Long-term management requires individualized dosing of desmopressin, patient education regarding fluid intake, and monitoring for hyponatremia or recurrent dehydration. Future advances may include regenerative or targeted molecular therapies for selected hereditary cases.
Vasopressin deficiency arises from disruptions in hormone synthesis, neuronal transport, or regulated secretion and most commonly manifests as central diabetes insipidus. Its molecular basis includes AVP gene mutations as well as traumatic, inflammatory, neoplastic, and postoperative lesions of the hypothalamic-pituitary axis. Prompt recognition and targeted treatment are essential to prevent dehydration and electrolyte imbalance. Improved understanding of molecular mechanisms continues to enhance diagnosis and patient outcomes. Vasopressin deficiency develops through defects in hormone synthesis, neuronal transport, storage, or secretion and most commonly presents as central diabetes insipidus. Its causes include inherited AVP gene abnormalities as well as traumatic, inflammatory, neoplastic, and postoperative lesions of the hypothalamic-pituitary system. Accurate molecular understanding supports timely diagnosis and effective treatment. Early intervention significantly reduces complications related to dehydration, hypernatremia, and impaired quality of life.
[1] Robertson GL. Diabetes insipidus. Endocrinol Metab Clin North Am. 1995;24(3):549–572.
[2] Bichet DG. Vasopressin disorders in humans. Kidney Int. 2006;69(2):212–220.
[3] Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab. 2003;17(4):471–503.
[4] Maghnie M. Diabetes insipidus. Horm Res. 2003;59(Suppl 1):42–54.
[5] Baylis PH. The syndrome of vasopressin deficiency. Clin Endocrinol. 1989;30(4):321–332.
[6] Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005;16(10):2836–2846.
[7] Christensen JH, Siggaard C, Corydon TJ, et al. Mutations in the AVP gene and familial neurohypophyseal diabetes insipidus. Hum Genet. 2004;115(1):44–51.
[8] Ito M, Mori Y, Oiso Y, Saito H. Clinical review of central diabetes insipidus. Endocr J. 2016;63(10):873–884.
[9] Arima H, Oiso Y. Mechanisms of central diabetes insipidus. Clin Endocrinol. 2010;73(4):413–418.
[10] Di Iorgi N, Napoli F, Allegri AEM, et al. Diabetes insipidus diagnosis and management. Horm Res Paediatr. 2012;77(2):69–84.
[11] Verbalis JG. AVP receptor signaling and water balance. Am J Med Sci. 2007;333(5):267–272.
[12] Bankir L, Bichet DG, Morgenthaler NG. Vasopressin physiology and biomarkers. Kidney Int. 2017;91(3):529–541.
[13] Fenske W, Refardt J, Chifu I, et al. Copeptin in diagnosis of vasopressin disorders. N Engl J Med. 2018;379(5):428–439.
[14] Oiso Y, Robertson GL, Nørgaard JP, Juul KV. Treatment of central diabetes insipidus. Nat Rev Endocrinol. 2013;9(9):530–540.
[15] Nielsen S, Frøkiaer J, Marples D, et al. Aquaporins and vasopressin-regulated water transport. Physiol Rev. 2002;82(1):205–244.
[16] Schrier RW. Water balance and arginine vasopressin. N Engl J Med. 2006;354(20):2142–2151.
[17] Robertson GL, Berl T. Pathophysiology of polyuria syndromes. Kidney Int. 1996;49(6):1712–1719.
[18] Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen CJ. Williams Textbook of Endocrinology. 14th ed. Elsevier; 2020.
[19] Med1.uz. Qandsiz diabet: sabablari va davolash. Available from: https://med1.uz/articles/endokrinologiya/qandsiz-diabet
[20] Med1.uz. Gipotalamo-gipofizar tizim kasalliklari. Available from: https://med1.uz/articles/endokrinologiya/gipofiz-kasalliklari
[21] Med1.uz. Suv-tuz almashinuvi buzilishlari. Available from: https://med1.uz/articles/terapiya/suv-tuz-almashinuvi
[22] Med1.uz. Buyraklarda suv reabsorbsiya mexanizmlari. Available from: https://med1.uz/articles/nefrologiya/reabsorbsiya
[23] Med1.uz. Gormonal kasalliklarda laborator diagnostika. Available from: https://med1.uz/articles/endokrinologiya/laborator-diagnostika